---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-133192"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T01:08:46.497290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q1 net loss narrows to $27.4M; cash $207.6M, pipeline advances with RNA editing candidate toward CTA

## Summary
- Q1 revenue $12.9M from GSK/Takeda collaborations vs $1.8M a year ago; net loss $27.4M vs $37.8M.
- Cash $207.6M at March 31, 2023 (up from $88.5M Dec 2022) provides runway into 2025, plus potential GSK milestones.
- WVE-006, first-in-class RNA editing candidate for AATD, on track for CTA submissions in 2H 2023.
- WVE-N531 for DMD: potentially registrational Phase 2 trial to start 2023 with dystrophin primary endpoint; data expected 2024.
- WVE-003 HD data delayed to 2H 2023 due to cyber attack at assay vendor; no Wave data compromised.

## SEC filing metadata
- accession: 0001193125-23-133192
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/0001193125-23-133192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/d42603d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-133192
- JSON: https://secwatch.observer/filing/0001193125-23-133192.json
- Plain text: https://secwatch.observer/filing/0001193125-23-133192.txt

## Key facts
- Earnings Releases
  Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 3, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/0001193125-23-133192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.